Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Russian CRO acquires clinical research company in Argentina

This article was originally published in Scrip

Executive Summary

The St Petersburg-based contract drug development company PSI has completed the acquisition of Thywill, a CRO headquartered in Buenos Aires, Argentina. Thywill specialises in clinical trials management across Latin America, and PSI hopes to benefit from this experience and expand its operations in Argentina, Peru, Ecuador, Uruguay, Colombia, Chile and Mexico. In addition to Russia and other ex-Soviet republics, PSI operates across Europe, and in North and South Americas. It employs more than 200 people in 22 countries who have experience in multinational regulatory issues relating to clinical research. In the 15 years passed since its establishment, the company completed more than 300 studies in all major therapeutic areas and more than 400 sponsor audits.

Topics

UsernamePublicRestriction

Register

SC003316

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel